Allergan plc Ordinary Shares (AGN) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 299 from a previous price target of $305 . Mizuho advised their investors in a research report released on Oct 11, 2016.
Many Wall Street Analysts have commented on Allergan plc Ordinary Shares. Company shares were Upgraded by Mizuho on Aug 19, 2016 to ” Buy”, Firm has raised the Price Target to $ 318 from a previous price target of $248 .Shares were Reiterated by RBC Capital Mkts on Aug 9, 2016 to “Outperform” and Lowered the Price Target to $ 300 from a previous price target of $307 .Shares were Reiterated by Deutsche Bank on Aug 9, 2016 to “Buy” and Lowered the Price Target to $ 278 from a previous price target of $282 .
On the company’s financial health, Allergan plc Ordinary Shares reported $3.35 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 8, 2016. Analyst had a consensus of $3.32. The company had revenue of $3709.00 million for the quarter, compared to analysts expectations of $3977.46 million. The company’s revenue was up 1.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $4.41 EPS.
Allergan plc Ordinary Shares opened for trading at $238.44 and hit $240.41 on the upside on Friday, eventually ending the session at $238.92, with a gain of 0.64% or 1.51 points. The heightened volatility saw the trading volume jump to 36,06,553 shares. Company has a market cap of $94,601 M.
In a different news, on Aug 9, 2016, Nesli Basgoz (director) sold 758 shares at $253.02 per share price. According to the SEC, on Jun 6, 2016, Maria Teresa Hilado (CFO) purchased 661 shares at $241.57 per share price. On Aug 24, 2015, Brent L Saunders (CEO) purchased 1,000 shares at $301.94 per share price, according to the Form-4 filing with the securities and exchange commission.